When will Romiplostim be available?

In August 2008, the U.S. Food and Drug Administration (FDA) approved romiplostim (Romiplostim) as a treatment for corticosteroids, intravenous immunoglobulin, Rho(D) immunoglobulin, or The long-term treatment of chronic immune thrombocytopenia (ITP) in adults who have not responded to other treatments such as splenectomy is being developed by Amgen through a restricted-use program called NEXUS. In 2022, the State Food and Drug Administration has approved the domestic marketing of romigrastim. Romigrastim is a potential treatment for chronic idiopathic (immune) thrombocytopenic purpura (ITP) and can also be used to treat acute radiation syndrome.